BMS reports 2% rise in total revenue in Q2 2022
Revenues grew 12% to $8.3bn in the US for the three months ended on 30 June.

Revenues grew 12% to $8.3bn in the US for the three months ended on 30 June.
Under the supply deal, Quoin is entitled for manufacturing and supplying QRX003 to Endo.
The NDS submission is based on positive findings from the Phase III programme and two long-term trials of roflumilast cream…
Despite a safety disclosure for one of the two anti-baldness assets on the market, demand for new treatments remains strong.
ByWith the FDA calling for more data on the JAK inhibitor in vitiligo, Incyte’s presentation is one to look out…
ByThrough the deal extension, ER-Kim gained exclusive rights to commercialise QRX003 in six additional countries.
Arena’s portfolio includes several candidates in gastroenterology, dermatology and cardiology.
The availability of new atopic dermatitis therapies in the US and Europe has been affected by differences in regulatory policy.
ByThank you for subscribing to Pharmaceutical Technology